购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

CD70 Protein, Human, Recombinant (rFc)

产品编号 TMPY-04982
CD70 Protein, Human, Recombinant (rFc) is expressed in HEK293 mammalian cells with rFc tag. The predicted molecular weight is 44.6 kDa and the accession number is A0A0U5JA32.
规格价格库存数量
100 μg
¥ 3,430
5日内发货
大包装 & 定制
加入购物车
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
实验操作小课堂
常见问题解答
准备进行动物实验,收到大包装粉末后,如何分装溶解?
根据配制出来的溶液是不是澄清的确定一次性能配多少:如果配制出来是澄清溶液,可以一次性多配制一些,储存于4度冰箱,大概一周配一次,放久了可能会失效;如果配制出来是混悬液,建议每次使用的时候都现配现用。
细胞实验中需要加多少抑制剂?
通常建议您参考同模型实验发表的文献报道;除参考文献报道以外,还需要通过预实验做“剂量-效应曲线”确定最佳作用浓度(浓度梯度);通过“时间-效应曲线”确定最佳孵育时间(处理时间梯度)。另外,抑制剂的使用量受多种因素影响,包括抑制对象的可接触性、细胞通透性、孵育时间、细胞种类等等。我们建议通过检索文献确定使用抑制剂的起始浓度。 如果有报道的 Ki 值或 IC50 值,可以采用其 5-10 倍的量开始尝试以达到抑制酶活性的最佳效果。 如果抑制剂的 Ki 值或 IC50 值未知,则需要在更广泛的范围尝试抑制剂的使用浓度,并采用 Michaelis-Menten 动力学计算 Ki 值。 一般设立溶解抑制剂时所采用的溶剂作为对照,以排除溶剂的非特异性影响。
抑制剂是否需要灭菌?
如果您使用 DMSO 配制:不建议灭菌,DMSO 本身具有极强的杀菌力,配制好的溶液就是无菌溶液。如果您确实担心的,可以放置 4℃ 冰箱过夜放置即可;依然有顾虑的话,需用有机系专用滤膜过滤。 如果您使用水配制:可以用 0.22 μm 滤膜过滤灭菌。
如何设置母液浓度?
母液浓度需低于官网给出的溶解度,在这个范围内,根据工作液浓度设置母液浓度,细胞实验中,建议母液浓度设定在工作液浓度的 1000 倍以上。
动物实验常用溶解方法?
首先,您需要确认给药剂量、给药方式。对于具体的产品,优先找引用我们产品的文献里的使用方法,再找其他文献里的配方。 如果没有相关的文献,且该化合物的 DMSO 溶解度比较好,我们推荐通用配方: 10% DMSO+40% PEG300+5% Tween-80+45% Saline/PBS/ddH2O。溶剂依次加入,尽量溶解后再加入下一个溶剂。正常鼠建议 DMSO 浓度在 10% 以下,裸鼠体弱鼠等配方的 DMSO 浓度建议在 2% 以下,根据溶液是否澄清,助溶剂 PEG300、Tween-80 的比例可以适当调整。如果有其他助溶剂也可以使用。 以上配方仅供参考,体内配方并不是绝对的,需要根据不同情况进行调整。建议先取少量化合物测试配方,再进行大量配制。配完也可以再使用超声、加热等方式助溶,看看能不能澄清一点。 腹腔注射对粉末的溶解度要求比较高,建议购买盐形式化合物。如果给药剂量比较大,也有报道使用混悬液进行腹腔给药的。 对于灌胃给药,且剂量比较大的情况下,建议用 0.5% CMC-Na 配置成均匀混悬液进行给药。
查看更多

产品信息

生物活性
Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
产品描述
CD70 Protein, Human, Recombinant (rFc) is expressed in HEK293 mammalian cells with rFc tag. The predicted molecular weight is 44.6 kDa and the accession number is A0A0U5JA32.
种属
Human
表达系统
HEK293 Cells
标签N-rFc
蛋白编号P32970-1
别名
TNFSF7,CD70 molecule,CD27LG,CD27L
蛋白构建
A DNA sequence encoding the human CD70 (NP_001243.1) (Gln39-Pro193) was expressed with the Fc region of rabbit IgG at the N-terminus.. Predicted N terminal: Ser
蛋白纯度
> 85 % as determined by SDS-PAGE.
分子量44.6 kDa (predicted)
内毒素< 1.0 EU/μg of the protein as determined by the LAL method.
缓冲液Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
复溶方法
A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
存储
It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式In general, Lyophilized powders are shipping with blue ice.
研究背景
CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.Cancer ImmunotherapyCo-stimulatory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy

SCI 文献

计算器

  • 复溶 计算器
  • 重组蛋白稀释 计算器
  • 比活力 计算器

技术支持

请阅读 重组蛋白用户指南 了解更多具体信息.

关键词